Literature DB >> 11896086

Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.

Mark J Ratain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11896086     DOI： 10.1200/JCO.2002.20.6.1434

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Prescribing oral chemotherapy.

Authors:  Sandeep D Parsad; Mark J Ratain
Journal:  BMJ       Date:  2007-02-24

Review 2.  Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing.

Authors:  Morgan A Casal; Thomas D Nolin; Jan H Beumer
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-19       Impact factor: 8.237

Review 3.  Drug development and clinical trials--the path to an approved cancer drug.

Authors:  Eric H Rubin; D Gary Gilliland
Journal:  Nat Rev Clin Oncol       Date:  2012-02-28       Impact factor: 66.675

4.  Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.

Authors:  Michelle A Rudek; Richard A Graham; Mark J Ratain
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

5.  A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.

Authors:  Michael Jefford; Michael Michael; Mark A Rosenthal; Ian D Davis; Michael Green; Bev McClure; Jennifer Smith; Brigid Waite; John Zalcberg
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

Review 6.  Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.

Authors:  Antona J Wagstaff; Tim Ibbotson; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  'The same old story': thoughts on authorized doses of anticancer drugs.

Authors:  Fausto Meriggi; Alberto Zaniboni
Journal:  Ther Adv Med Oncol       Date:  2020-02-22       Impact factor: 8.168

8.  Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports.

Authors:  K Brickell; D Porter; P Thompson
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

Review 9.  Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?

Authors:  Jonathan E Knikman; Hans Gelderblom; Jos H Beijnen; Annemieke Cats; Henk-Jan Guchelaar; Linda M Henricks
Journal:  Clin Pharmacol Ther       Date:  2020-11-12       Impact factor: 6.875
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.